Biogen
BIIB
$219.07
+1.66%
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing therapies for neurodegenerative and rare diseases, with its portfolio spanning multiple sclerosis (MS), spinal muscular atrophy, Alzheimer's disease, Friedreich's ataxia, postpartum depression, and ALS, alongside oncology and MS revenue from its CD20 collaboration with Roche. The company is a mid-cap ($32.3B market cap) established player in the general drug manufacturing space, distinct for its deep neuroscience franchise and its transition from a legacy MS-dependent model toward a diversified rare-disease and immunology platform. The current investor narrative centers on whether Biogen's strategic pivot — highlighted by the completed acquisition of Apellis Pharmaceuticals, the up-to-$1 billion RayThera immunology deal, and the Q2 2026 revenue beat with raised guidance — can offset the May 2026 Alzheimer's drug diranersen trial miss that spooked investors despite strong secondary cognitive data. Analysts remain largely constructive, with recent upgrades from Truist Securities and Needham, though debate persists over pipeline execution risk, the declining MS franchise, and whether the stock's 49.9% one-year rally has already priced in the turnaround.…
BIIB
Biogen
$219.07
Related headlines
Investment Opinion: Should I buy BIIB Today?
Rating: Buy. The synthesized recommendation is Buy, anchored by the analyst consensus rating of Buy (mean 1.89 from 31 analysts) and an average target price of $238.18, implying 10.5% upside from the current $215.50. The core thesis is that Biogen is a deeply undervalued biopharma with a forward PE of 13.03x, a robust pipeline of rare disease and immunology assets, and a fortress balance sheet (debt-to-equity of 0.38) that provides downside protection while the strategic pivot gains traction.
Supporting evidence includes: (1) valuation — forward PE of 13.03x and price-to-book of 1.41x are well below the broader healthcare sector and the stock's own historical averages; (2) growth trajectory — while Q1 2026 revenue grew only 1.9% YoY, the Q2 2026 beat and raised guidance suggest acceleration, and the Apellis acquisition adds immediate revenue; (3) profitability — gross margin of 70.5%, operating margin of 19.1%, and net margin of 13.2% demonstrate strong underlying profitability; (4) cash flow — trailing free cash flow of $2.62 billion provides ample resources for M&A and pipeline investment; and (5) analyst sentiment — the average target of $238.18 and high target of $300 reflect confidence in the turnaround, with recent upgrades from Truist and Needham.
Key risks that could invalidate the thesis include: (1) pipeline failure — the diranersen Alzheimer's miss in May 2026 shows the binary risk; a failure of the immunology or rare disease programs would be devastating; (2) continued MS erosion — if the 40% revenue base declines faster than new products ramp, revenue could turn negative; and (3) earnings volatility — the Q4 2025 GAAP loss of $0.33 per share highlights the unpredictability of results. The rating would upgrade to a strong Buy if forward PE compresses below 11x or if revenue growth accelerates above 5%, and would downgrade to Hold if revenue growth turns negative or if another major pipeline asset fails. Relative to its history and peers, BIIB appears undervalued, trading at a discount to the market and its own five-year average multiples, offering a favorable risk/reward for patient investors.
Sign up to view all
BIIB 12-Month Price Forecast
Biogen presents a compelling risk/reward for value-oriented investors with a medium-term horizon. The stock trades at a significant discount to the market on forward earnings, has a strong balance sheet, and generates substantial free cash flow, yet the market is pricing in considerable pipeline risk. The analyst community remains constructive with a Buy consensus and a $238.18 average target, but the high short ratio of 7.4 and the recent Alzheimer's trial miss highlight the binary nature of the story. I would upgrade to high confidence if the next major pipeline readout is positive or if revenue growth accelerates above 4%, and I would downgrade to neutral if the MS decline accelerates or if another key trial fails. The low beta of 0.17 means this is a stock-specific bet, not a macro play, so investors should focus on company execution.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Biogen's 12-month outlook, with a consensus price target around $238.18 and implied upside of +8.7% versus the current price.
Average Target
$238.18
0 analysts
Implied Upside
+8.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $300
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: BIIB Investment Factors
The bull case rests on Biogen's attractive forward valuation (13x PE), strong balance sheet (0.38 debt-to-equity), robust free cash flow ($2.62 billion), and analyst consensus target of $238.18 implying 10.5% upside. The bear case centers on the May 2026 Alzheimer's trial miss, earnings volatility (Q4 2025 GAAP EPS of -$0.33), a declining MS franchise that still represents 40% of revenue, and a high short ratio of 7.4. Currently, the bull evidence appears slightly stronger because the company has beaten revenue estimates, raised guidance, completed strategic acquisitions, and trades at a discount to its own history and the market, while the bear case relies heavily on pipeline risk that is already partially reflected in the stock price. The single most important tension is whether Biogen's pipeline — particularly in immunology and rare diseases following the Apellis and RayThera deals — can replace the declining MS revenue before the revenue cliff accelerates; if it can, the stock is undervalued; if not, the 49.9% one-year rally may reverse.
Bullish
- Analyst consensus sees 10.5% upside: 31 analysts rate BIIB a Buy (recommendation mean 1.89) with an average target price of $238.18 versus the current $215.50, implying 10.5% upside. The high target of $300 implies 39.2% upside, and even the low target of $175 is only 18.8% below the current price, suggesting limited downside per the analyst community.
- Deep value on forward earnings: BIIB trades at a forward PE of 13.03x and trailing PE of 19.89x, with a PEG ratio of -0.95 (negative due to trailing earnings distortions). The forward PE of 13x is well below the broader market and the healthcare sector, and the price-to-book of 1.41x and price-to-sales of 2.63x suggest the market is not paying a premium for the franchise.
- Strong balance sheet and cash generation: Biogen carries a debt-to-equity ratio of just 0.38 and a current ratio of 2.68, indicating ample liquidity. It generated $2.62 billion in trailing free cash flow, and with a net margin of 13.2% and operating margin of 19.1%, the company remains solidly profitable despite pipeline setbacks.
- Strategic pivot gaining traction: The Q2 2026 revenue beat and raised guidance, the completed Apellis acquisition, and the up-to-$1 billion RayThera immunology deal signal a successful diversification away from the declining MS franchise. The Motley Fool noted the Q2 beat and improved revenue guidance outweigh a lower profit forecast, and analysts from Truist and Needham have upgraded the stock.
Bearish
- Alzheimer's pipeline setback: The May 2026 diranersen trial missed its primary endpoint, causing a sharp selloff despite strong secondary cognitive data. This raises questions about Biogen's ability to develop a successful Alzheimer's therapy, a key pillar of its long-term growth narrative, and highlights the binary risk inherent in neuroscience drug development.
- Earnings volatility and negative GAAP EPS: Biogen reported a GAAP EPS of -$0.33 in Q4 2025 and a net loss of $48.4 million, following a Q1 2025 net income of $240.5 million and Q2 2025 net income of $634.8 million. This volatility, driven by acquisition-related charges and pipeline impairments, makes earnings difficult to predict and undermines the reliability of the trailing PE of 19.89x.
- Declining MS franchise concentration: The multiple sclerosis franchise contributed 40% of total revenue in 2025 and is declining, while the CD20 collaboration with Roche added another 19%. This concentration in legacy products facing generic and competitive pressure creates a revenue cliff that newer franchises like Leqembi and Skyclarys must fill, and the 1.9% YoY revenue growth in Q1 2026 shows the transition is slow.
- High short interest signals skepticism: The short ratio stands at 7.4, meaning it would take 7.4 days of average trading volume to cover all short positions. This elevated level indicates that a significant portion of the market is betting against the stock, likely due to pipeline execution risk and doubts about the sustainability of the recent rally.
BIIB Technical Analysis
Beta
0.17
0.17x market volatility
Max Drawdown
-14.3%
Largest decline past year
52-Week Range
$135-$226
Price range past year
Annual Return
+53.7%
Cumulative gain past year
| Period | BIIB Return | S&P 500 |
|---|---|---|
| 1m | +1.1% | +1.0% |
| 3m | +11.1% | +5.4% |
| 6m | +15.8% | +17.8% |
| 1y | +53.7% | +16.5% |
| ytd | +23.2% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BIIB Fundamental Analysis
Quarterly Revenue
$2.5B
2026-03
Revenue YoY Growth
+1.9%
YoY Comparison
Gross Margin
73.3%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BIIB Overvalued?
PE
19.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.6x
Enterprise Value Multiple
Investment Risk Disclosure
Biogen's financial and operational risks are significant but manageable. The company's revenue growth is anemic at 1.9% year-over-year in Q1 2026, and its largest franchise, multiple sclerosis, accounts for 40% of revenue and is in structural decline. Earnings are highly volatile: Q4 2025 produced a GAAP EPS of -$0.33 and a net loss of $48.4 million, while Q1 2026 rebounded to $2.17 EPS. This volatility stems from acquisition-related charges, pipeline impairments, and fluctuating collaboration revenue, making it difficult for investors to rely on trailing earnings. Additionally, the company's $2.62 billion in trailing free cash flow, while strong, must fund an aggressive M&A strategy (Apellis acquisition, up to $1 billion for RayThera) and pipeline development, leaving less room for shareholder returns given a 0% dividend yield and no buyback mentioned.
Market and competitive risks are pronounced. Biogen trades at a forward PE of 13.03x, which is low relative to the market but reflects skepticism about its growth prospects. If the pipeline fails to deliver, the stock could de-rate further. The beta of 0.17 indicates very low correlation with the broader market, meaning Biogen is largely a stock-specific story; sector rotation or macro shifts will have less impact, but company-specific news will dominate. Competitive threats are intensifying in Alzheimer's (Eli Lilly's donanemab), MS (generic competition and newer oral therapies), and rare diseases. The high short ratio of 7.4 suggests that negative sentiment could amplify downside moves if pipeline news disappoints. Recent news highlights the diranersen trial miss in May 2026, which caused a sharp selloff, and while analysts remained bullish, the event underscores the binary risk of clinical trials.
The worst-case scenario would involve a cascade of pipeline failures, particularly if the immunology bets (RayThera) and rare disease acquisitions (Apellis) do not yield commercial success, while the MS franchise erodes faster than expected. This could drive revenue growth negative and force further write-downs, leading to a re-rating toward the 52-week low of $135.39, which represents a 37.2% decline from the current price of $215.50. The analyst low target of $175 implies a more moderate 18.8% downside, but in a severe bear case, the stock could test the 52-week low, especially if the next Alzheimer's readout fails or if Leqembi uptake stalls. Given the max drawdown of -14.34% over the past 180 days, a 37% drawdown is plausible in a worst-case scenario, though the strong balance sheet and cash flow provide some valuation support.
FAQ
The most severe risk is pipeline failure, as evidenced by the May 2026 diranersen Alzheimer's trial miss, which caused a sharp selloff. Second, revenue concentration in the declining MS franchise (40% of 2025 revenue) poses a structural risk if new products do not ramp quickly. Third, earnings volatility is high, with Q4 2025 GAAP EPS of -$0.33 and a net loss, making it difficult to value on trailing earnings. Fourth, the high short ratio of 7.4 indicates negative sentiment that could amplify downside moves. Macro risks are lower due to the low beta of 0.17, but competitive threats in Alzheimer's and MS are intensifying.
The 12-month forecast is based on three scenarios: bull case (30% probability) with a target range of $260-$300, driven by pipeline success and multiple expansion; base case (50% probability) with a target range of $230-$250, assuming steady execution and low-single-digit revenue growth; and bear case (20% probability) with a target range of $135-$175, triggered by pipeline failures or accelerated MS decline. The base case is most likely, aligning with the analyst average target of $238.18. The key assumption is that Biogen's newer franchises offset MS erosion and that no major new pipeline setbacks occur.
BIIB appears undervalued on forward earnings, trading at a forward PE of 13.03x compared to a trailing PE of 19.89x, which implies the market expects earnings growth. The price-to-book of 1.41x and price-to-sales of 2.63x are also modest for a profitable biopharma with a 70.5% gross margin. However, the EV/EBITDA of 9.60x and price-to-cash-flow of 11.71x are not deep-value levels, suggesting the market is pricing in some pipeline risk. Relative to its own history, BIIB has traded at higher multiples, so the current valuation represents a discount, but the discount is justified by the declining MS franchise and pipeline uncertainty.
From a risk/reward perspective, BIIB offers a favorable setup for value-oriented investors. The stock trades at a forward PE of 13.03x, well below the market, and the analyst consensus target of $238.18 implies 10.5% upside, with the high target at $300 (39.2% upside). The biggest downside risk is pipeline failure, which could send the stock to the 52-week low of $135.39 (37.2% downside), but the strong balance sheet (debt-to-equity 0.38) and $2.62 billion free cash flow provide a cushion. It is a good buy for investors with a medium-term horizon who can tolerate binary events, but not for those seeking low volatility or income.
BIIB is better suited for medium-to-long-term investment (minimum 2-3 years) because the pipeline catalysts and strategic pivot will take time to materialize. The low beta of 0.17 and lack of dividend make it less attractive for short-term trading, but the binary nature of clinical trial readouts can create short-term volatility for traders. Long-term investors can benefit from the discounted valuation and potential multiple expansion as the turnaround progresses, while short-term traders might focus on event-driven moves around earnings or data releases. A holding period of at least 18-24 months is recommended to capture the full impact of the Apellis and RayThera acquisitions and pipeline readouts.
